The Drug Regulatory Authority of Pakistan (DRAP) has issued a public health alert warning consumer against purchasing or using a falsified presentation of Hexaxim vaccine, which is administered to infants and young children to protect them against six serious infectious diseases.
Follow Times of Karachi on Google News and add as a preferred Source on Google
According to the alert, Hoechst Pakistan Limited, Karachi, the local distributor of Sanofi products in Pakistan, informed DRAP about the availability of a suspicious Hexaxim vaccine bearing batch number X3H421VA.
The product is being presented in vial form and purportedly manufactured by Sanofi. However, the company has clarified that this particular presentation is not registered or authorised for import into Pakistan.
DRAP confirmed that Hexaxim is registered in Pakistan only in a pre-filled syringe presentation, not in vial form.
Which Hexaxim vaccine has been flagged?
The alert specifically identifies the following product:
- Product: Hexaxim vaccine
- Batch number: X3H421VA
- Presentation: Vial form
- Claimed manufacturer: Sanofi
- Regulatory status: Not registered or authorised for import into Pakistan
DRAP has advised consumers, healthcare professionals and medical suppliers to remain alert and avoid purchasing or administering the identified vial presentation.
What diseases does Hexaxim vaccine protect against?
Hexaxim is a ready-to-use, liquid hexavalent combination vaccine designed to protect infants and young children against six infectious diseases.
These include:
- Diphtheria
- Tetanus
- Pertussis, commonly known as whooping cough
- Hepatitis B
- Poliomyelitis, or polio
- Infections caused by Haemophilus influenzae type b (Hib)
The vaccine combines protection against these diseases in a single formulation as part of childhood immunisation.
DRAP warns of serious health risks
The regulatory authority has warned that the availability and use of the falsified vial presentation could create serious health risks.
These may include therapeutic failure, meaning the vaccine may not provide the expected protection, as well as possible adverse effects.
DRAP has directed its Regulatory Field Force and provincial drug control departments to increase surveillance across the supply chain.
The departments have also been instructed to identify and confiscate the falsified product wherever it is found.
What should parents and consumers do?
DRAP has advised parents and caregivers not to purchase or use Hexaxim vaccine bearing batch number X3H421VA in vial form.
Consumers should follow these precautions:
- Do not purchase or administer the identified vial presentation.
- Obtain vaccines and other therapeutic products only from licensed pharmacies and authorised retail outlets.
- Check product packaging, batch details and condition before use.
- Consult a pharmacist or healthcare professional if there are doubts about a vaccine’s authenticity.
- Avoid using products from unverified sellers or unauthorised sources.
Anyone who has already used the identified product and experiences a health-related problem should immediately contact a physician or healthcare provider.
Consumers and healthcare professionals should also report suspected adverse events or product-related concerns to DRAP or the National Pharmacovigilance Centre.
The alert is intended to prevent the circulation and use of the unauthorised vaccine presentation and protect children from potential health risks.
